The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Mumps Vaccine Market Research Report 2024
Synopsis
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.
Global Mumps Vaccine market is projected to reach US$ 454.2 million in 2029, increasing from US$ 369 million in 2022, with the CAGR of 3.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mumps Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mumps Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
MedImmune
Johnson & Johnson
Merck & Co., Inc.
Sanofi
Serum Institute of India
Bavarian Nordic
Astellas Pharma India
CSL Limited
Emergent BioSolutions
GlaxoSmithKline
Panacea Biotec, Ltd.
Biological E Limited
Bharat Biotech Ltd.
Novavax, Inc.
Novartis
Sinovac Biotech, Ltd.
Incepta Vaccine Limited
Valneva SE
VBI Vaccines
PT Bio Farma
Sharp & Dohme Corp
Bionity
Segment by Type
Child
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Mumps Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles). The first dose is generally given to children around 9 months to 15 months of age, with a second dose at 15 months to 6 years of age, with at least 4 weeks between the doses.
Global Mumps Vaccine market is projected to reach US$ 454.2 million in 2029, increasing from US$ 369 million in 2022, with the CAGR of 3.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mumps Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Mumps Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
MedImmune
Johnson & Johnson
Merck & Co., Inc.
Sanofi
Serum Institute of India
Bavarian Nordic
Astellas Pharma India
CSL Limited
Emergent BioSolutions
GlaxoSmithKline
Panacea Biotec, Ltd.
Biological E Limited
Bharat Biotech Ltd.
Novavax, Inc.
Novartis
Sinovac Biotech, Ltd.
Incepta Vaccine Limited
Valneva SE
VBI Vaccines
PT Bio Farma
Sharp & Dohme Corp
Bionity
Segment by Type
Child
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Mumps Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Mumps Vaccine Market Overview
1.1 Product Overview and Scope of Mumps Vaccine
1.2 Mumps Vaccine Segment by Type
1.2.1 Global Mumps Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Child
1.2.3 Adult
1.3 Mumps Vaccine Segment by Application
1.3.1 Global Mumps Vaccine Market Value by Application: (2023-2029)
1.3.2 Hospitals Pharmacies
1.3.3 Retail Pharmacies
1.4 Global Mumps Vaccine Market Size Estimates and Forecasts
1.4.1 Global Mumps Vaccine Revenue 2018-2029
1.4.2 Global Mumps Vaccine Sales 2018-2029
1.4.3 Global Mumps Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Mumps Vaccine Market Competition by Manufacturers
2.1 Global Mumps Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Mumps Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Mumps Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Mumps Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Mumps Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Mumps Vaccine, Product Type & Application
2.7 Mumps Vaccine Market Competitive Situation and Trends
2.7.1 Mumps Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Mumps Vaccine Players Market Share by Revenue
2.7.3 Global Mumps Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Mumps Vaccine Retrospective Market Scenario by Region
3.1 Global Mumps Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Mumps Vaccine Global Mumps Vaccine Sales by Region: 2018-2029
3.2.1 Global Mumps Vaccine Sales by Region: 2018-2023
3.2.2 Global Mumps Vaccine Sales by Region: 2024-2029
3.3 Global Mumps Vaccine Global Mumps Vaccine Revenue by Region: 2018-2029
3.3.1 Global Mumps Vaccine Revenue by Region: 2018-2023
3.3.2 Global Mumps Vaccine Revenue by Region: 2024-2029
3.4 North America Mumps Vaccine Market Facts & Figures by Country
3.4.1 North America Mumps Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Mumps Vaccine Sales by Country (2018-2029)
3.4.3 North America Mumps Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Mumps Vaccine Market Facts & Figures by Country
3.5.1 Europe Mumps Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Mumps Vaccine Sales by Country (2018-2029)
3.5.3 Europe Mumps Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Mumps Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Mumps Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Mumps Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Mumps Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Mumps Vaccine Market Facts & Figures by Country
3.7.1 Latin America Mumps Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Mumps Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Mumps Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Mumps Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Mumps Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Mumps Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Mumps Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Mumps Vaccine Sales by Type (2018-2029)
4.1.1 Global Mumps Vaccine Sales by Type (2018-2023)
4.1.2 Global Mumps Vaccine Sales by Type (2024-2029)
4.1.3 Global Mumps Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Mumps Vaccine Revenue by Type (2018-2029)
4.2.1 Global Mumps Vaccine Revenue by Type (2018-2023)
4.2.2 Global Mumps Vaccine Revenue by Type (2024-2029)
4.2.3 Global Mumps Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Mumps Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Mumps Vaccine Sales by Application (2018-2029)
5.1.1 Global Mumps Vaccine Sales by Application (2018-2023)
5.1.2 Global Mumps Vaccine Sales by Application (2024-2029)
5.1.3 Global Mumps Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Mumps Vaccine Revenue by Application (2018-2029)
5.2.1 Global Mumps Vaccine Revenue by Application (2018-2023)
5.2.2 Global Mumps Vaccine Revenue by Application (2024-2029)
5.2.3 Global Mumps Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Mumps Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 MedImmune
6.1.1 MedImmune Corporation Information
6.1.2 MedImmune Description and Business Overview
6.1.3 MedImmune Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 MedImmune Mumps Vaccine Product Portfolio
6.1.5 MedImmune Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Johnson & Johnson Mumps Vaccine Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Merck & Co., Inc.
6.3.1 Merck & Co., Inc. Corporation Information
6.3.2 Merck & Co., Inc. Description and Business Overview
6.3.3 Merck & Co., Inc. Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Merck & Co., Inc. Mumps Vaccine Product Portfolio
6.3.5 Merck & Co., Inc. Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Sanofi Mumps Vaccine Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Serum Institute of India
6.5.1 Serum Institute of India Corporation Information
6.5.2 Serum Institute of India Description and Business Overview
6.5.3 Serum Institute of India Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute of India Mumps Vaccine Product Portfolio
6.5.5 Serum Institute of India Recent Developments/Updates
6.6 Bavarian Nordic
6.6.1 Bavarian Nordic Corporation Information
6.6.2 Bavarian Nordic Description and Business Overview
6.6.3 Bavarian Nordic Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Bavarian Nordic Mumps Vaccine Product Portfolio
6.6.5 Bavarian Nordic Recent Developments/Updates
6.7 Astellas Pharma India
6.6.1 Astellas Pharma India Corporation Information
6.6.2 Astellas Pharma India Description and Business Overview
6.6.3 Astellas Pharma India Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Astellas Pharma India Mumps Vaccine Product Portfolio
6.7.5 Astellas Pharma India Recent Developments/Updates
6.8 CSL Limited
6.8.1 CSL Limited Corporation Information
6.8.2 CSL Limited Description and Business Overview
6.8.3 CSL Limited Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 CSL Limited Mumps Vaccine Product Portfolio
6.8.5 CSL Limited Recent Developments/Updates
6.9 Emergent BioSolutions
6.9.1 Emergent BioSolutions Corporation Information
6.9.2 Emergent BioSolutions Description and Business Overview
6.9.3 Emergent BioSolutions Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Emergent BioSolutions Mumps Vaccine Product Portfolio
6.9.5 Emergent BioSolutions Recent Developments/Updates
6.10 GlaxoSmithKline
6.10.1 GlaxoSmithKline Corporation Information
6.10.2 GlaxoSmithKline Description and Business Overview
6.10.3 GlaxoSmithKline Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 GlaxoSmithKline Mumps Vaccine Product Portfolio
6.10.5 GlaxoSmithKline Recent Developments/Updates
6.11 Panacea Biotec, Ltd.
6.11.1 Panacea Biotec, Ltd. Corporation Information
6.11.2 Panacea Biotec, Ltd. Mumps Vaccine Description and Business Overview
6.11.3 Panacea Biotec, Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Panacea Biotec, Ltd. Mumps Vaccine Product Portfolio
6.11.5 Panacea Biotec, Ltd. Recent Developments/Updates
6.12 Biological E Limited
6.12.1 Biological E Limited Corporation Information
6.12.2 Biological E Limited Mumps Vaccine Description and Business Overview
6.12.3 Biological E Limited Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biological E Limited Mumps Vaccine Product Portfolio
6.12.5 Biological E Limited Recent Developments/Updates
6.13 Bharat Biotech Ltd.
6.13.1 Bharat Biotech Ltd. Corporation Information
6.13.2 Bharat Biotech Ltd. Mumps Vaccine Description and Business Overview
6.13.3 Bharat Biotech Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Bharat Biotech Ltd. Mumps Vaccine Product Portfolio
6.13.5 Bharat Biotech Ltd. Recent Developments/Updates
6.14 Novavax, Inc.
6.14.1 Novavax, Inc. Corporation Information
6.14.2 Novavax, Inc. Mumps Vaccine Description and Business Overview
6.14.3 Novavax, Inc. Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Novavax, Inc. Mumps Vaccine Product Portfolio
6.14.5 Novavax, Inc. Recent Developments/Updates
6.15 Novartis
6.15.1 Novartis Corporation Information
6.15.2 Novartis Mumps Vaccine Description and Business Overview
6.15.3 Novartis Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Novartis Mumps Vaccine Product Portfolio
6.15.5 Novartis Recent Developments/Updates
6.16 Sinovac Biotech, Ltd.
6.16.1 Sinovac Biotech, Ltd. Corporation Information
6.16.2 Sinovac Biotech, Ltd. Mumps Vaccine Description and Business Overview
6.16.3 Sinovac Biotech, Ltd. Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sinovac Biotech, Ltd. Mumps Vaccine Product Portfolio
6.16.5 Sinovac Biotech, Ltd. Recent Developments/Updates
6.17 Incepta Vaccine Limited
6.17.1 Incepta Vaccine Limited Corporation Information
6.17.2 Incepta Vaccine Limited Mumps Vaccine Description and Business Overview
6.17.3 Incepta Vaccine Limited Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Incepta Vaccine Limited Mumps Vaccine Product Portfolio
6.17.5 Incepta Vaccine Limited Recent Developments/Updates
6.18 Valneva SE
6.18.1 Valneva SE Corporation Information
6.18.2 Valneva SE Mumps Vaccine Description and Business Overview
6.18.3 Valneva SE Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Valneva SE Mumps Vaccine Product Portfolio
6.18.5 Valneva SE Recent Developments/Updates
6.19 VBI Vaccines
6.19.1 VBI Vaccines Corporation Information
6.19.2 VBI Vaccines Mumps Vaccine Description and Business Overview
6.19.3 VBI Vaccines Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.19.4 VBI Vaccines Mumps Vaccine Product Portfolio
6.19.5 VBI Vaccines Recent Developments/Updates
6.20 PT Bio Farma
6.20.1 PT Bio Farma Corporation Information
6.20.2 PT Bio Farma Mumps Vaccine Description and Business Overview
6.20.3 PT Bio Farma Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.20.4 PT Bio Farma Mumps Vaccine Product Portfolio
6.20.5 PT Bio Farma Recent Developments/Updates
6.21 Sharp & Dohme Corp
6.21.1 Sharp & Dohme Corp Corporation Information
6.21.2 Sharp & Dohme Corp Mumps Vaccine Description and Business Overview
6.21.3 Sharp & Dohme Corp Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Sharp & Dohme Corp Mumps Vaccine Product Portfolio
6.21.5 Sharp & Dohme Corp Recent Developments/Updates
6.22 Bionity
6.22.1 Bionity Corporation Information
6.22.2 Bionity Mumps Vaccine Description and Business Overview
6.22.3 Bionity Mumps Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Bionity Mumps Vaccine Product Portfolio
6.22.5 Bionity Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Mumps Vaccine Industry Chain Analysis
7.2 Mumps Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Mumps Vaccine Production Mode & Process
7.4 Mumps Vaccine Sales and Marketing
7.4.1 Mumps Vaccine Sales Channels
7.4.2 Mumps Vaccine Distributors
7.5 Mumps Vaccine Customers
8 Mumps Vaccine Market Dynamics
8.1 Mumps Vaccine Industry Trends
8.2 Mumps Vaccine Market Drivers
8.3 Mumps Vaccine Market Challenges
8.4 Mumps Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
